1,796 material Form 8-K filings that 1,448 companies we cover made with the SEC in May 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Hormel reported fiscal second-quarter 2026 net sales of $2.97 billion, up 2.5% from a year earlier, but GAAP operating income fell to $217 million from $248 million and GAAP diluted EPS was $0.29 versus $0.33. The company lowered its fiscal 2026 GAAP diluted EPS guidance to $1.28 to $1.37 from $1.37 to $1.46, reflecting the $61 million loss on the whole-bird turkey sale, while reaffirming adjusted diluted EPS guidance of $1.43 to $1.51.
Q2 net sales $2.97 billion, up 2.5%; organic net sales up 3%
Q2 GAAP diluted EPS $0.29 vs $0.33 a year earlier; adjusted diluted EPS $0.40 vs $0.35
Fiscal 2026 GAAP diluted EPS guidance cut to $1.28 to $1.37 from $1.37 to $1.46; adjusted EPS guidance reaffirmed at $1.43 to $1.51
Loss on the whole-bird turkey business sale, including transaction costs, was $61 million in the quarter
Artelo Biosciences entered a sales agreement with H.C. Wainwright & Co. allowing it to sell up to $6,530,000 of common stock through an at-the-market program, paying the agent a 3.0% commission on gross sales. Separately, Craft Capital Management filed a FINRA arbitration claim against the company over a right of first refusal tied to a March 2026 private placement. The stock sales could dilute existing shareholders, and the outcome of the arbitration is not addressed in the filing.
Sales agreement dated May 26, 2026 allows sales of up to $6,530,000 of common stock, par value $0.001 per share
Sales agent receives a 3.0% commission on gross sales price; company has no obligation to sell any shares
Craft Capital seeks an $880,000 success fee, warrants valued at $880,000, monthly late fees and attorneys' fees over the March 30, 2026 private placement, which raised gross proceeds of about $11 million
Minerva Neurosciences entered a Sales Agreement with Leerink Partners LLC for an at-the-market offering of up to $75.0 million of common stock, with a 3.0% commission on gross proceeds. The company is not obligated to sell any shares, so the program could dilute existing shareholders if used. The filing also says the relapse assessment phase of its Phase 3 C19 trial of roluperidone was extended from 40 weeks to 52 weeks after FDA feedback, with topline results still expected in the second half of 2027.
Up to $75.0 million of common stock may be sold through Leerink Partners LLC, under a prospectus supplement dated May 27, 2026
Agent commission is 3.0% of gross proceeds; the company has no obligation to sell any shares
Relapse assessment phase of the C19 trial extended from 40 weeks to 52 weeks after FDA feedback
Topline efficacy results still expected in the second half of 2027; relapse assessment data in the second half of 2028
HP reported fiscal 2026 second-quarter results on May 27, 2026, with net revenue of $14.4 billion, up 9.0%, and non-GAAP diluted EPS of $0.86, up 21.1%. GAAP diluted EPS of $0.49 was below the company's prior outlook of $0.52 to $0.58, and restructuring and other charges reached $365 million, and HP updated its fiscal 2026 EPS and free cash flow estimates.
Net revenue of $14.4 billion, up 9.0% year over year; GAAP diluted EPS of $0.49, up from $0.42 but below the prior outlook of $0.52 to $0.58
Non-GAAP diluted EPS of $0.86, up from $0.71 and above the prior outlook of $0.70 to $0.76
Restructuring and other charges of $365 million in the quarter, compared with $122 million a year earlier
Fiscal 2026 estimates: GAAP diluted EPS $2.15 to $2.45, non-GAAP diluted EPS $2.90 to $3.10, free cash flow $2.8 to $3.0 billion
Passage Bio gave written notice on May 21, 2026 to end its research, collaboration and license agreement with Gemma Biotherapeutics, and on May 22, 2026 agreed with its landlord to terminate its 37,000-square-foot office lease at 2005 Market Street. The company agreed to pay a $2.3 million lease termination fee, and the Gemma termination takes effect under the agreement's terms. For shareholders, the filing shows the company is ending a partnership and reducing its office footprint, though the filing does not describe the financial effect beyond the fee.
Gemma Collaboration Agreement, dated July 31, 2024, terminated by written notice on May 21, 2026
Gemma had conducted preclinical and IND-enabling work for the Huntington's disease program and a paused Temporal Lobe Epilepsy program
Lease termination agreement signed May 22, 2026 with Commerce Square Partners; $2.3 million termination fee
Leased space was about 37,000 square feet, with a lease originally set to expire in December 2031; substantially all of it was subleased in 2023
Synopsys reported second-quarter fiscal 2026 revenue of $2.276 billion, up from $1.604 billion a year earlier, and raised its full-year revenue and non-GAAP EPS targets. GAAP net income fell to $17.1 million, or $0.09 per diluted share, from $349.2 million a year earlier, and included $115.9 million in restructuring charges.
Q2 revenue $2.276 billion vs $1.604 billion a year earlier; non-GAAP EPS $3.35 vs $3.67.
GAAP net income $17.1 million ($0.09 per diluted share) vs $349.2 million ($2.24) a year earlier.
Full-year fiscal 2026 revenue midpoint raised to $9.665 billion from $9.610 billion; non-GAAP EPS midpoint raised to $14.76.
Marvell reported first-quarter fiscal 2027 revenue of $2.418 billion, a record and up 28% from a year earlier, and guided second-quarter revenue to $2.7 billion at the mid-point. GAAP net income fell to $34.5 million, or $0.04 per diluted share, from $177.9 million a year earlier, mainly because of a $250.7 million special item, while non-GAAP diluted EPS rose to $0.80 from $0.62. The company said it is raising its revenue outlook for both fiscal 2027 and fiscal 2028.
Q1 fiscal 2027 net revenue was $2.418 billion, up 28% year over year and $18.0 million above the mid-point of guidance given March 5, 2026
GAAP diluted EPS was $0.04 versus $0.20 a year earlier; non-GAAP diluted EPS was $0.80 versus $0.62
Q2 fiscal 2027 revenue guidance is $2.700 billion, plus or minus 5%, with non-GAAP diluted EPS guided to $0.93, plus or minus $0.05
Abercrombie & Fitch reported first-quarter fiscal 2026 net sales of $1.1 billion, up 2% from last year, with comparable sales down 1%. Diluted earnings per share fell to $1.47 from $1.59, and operating margin fell to 8.0% from 9.3%, though the company said EPS exceeded its outlook range. The company kept its full-year outlook unchanged, which matters to shareholders because it signals no change to its earnings or sales targets despite weaker EMEA demand.
Net sales of $1.1 billion, up 2%; comparable sales down 1%; EMEA sales down 10%, APAC up 24%
Diluted EPS of $1.47 vs. $1.59 a year earlier; operating margin of 8.0% vs. 9.3%
Full-year outlook maintained: net sales growth of 3% to 5%, diluted EPS of $10.20 to $11.00, share repurchases of around $450 million
Repurchased $105 million of shares in the quarter, with $745 million remaining on the March 2025 authorization
Bath & Body Works reported first quarter 2026 net sales of $1,378 million, down 3% from a year earlier, and reaffirmed its full-year 2026 guidance. Reported earnings per diluted share rose to $0.90 from $0.49, but that figure includes an $88 million pre-tax litigation settlement gain and a $62 million tax benefit, while adjusted EPS was $0.32 versus $0.49 last year. Chief Financial Officer Eva Boratto will step down June 12, and Tom Javitch will serve as interim CFO while the company searches for a successor.
Q1 2026 net sales were $1,378 million, down 3% from $1,424 million in Q1 2025.
Reported diluted EPS was $0.90 versus $0.49; adjusted diluted EPS was $0.32 versus $0.49.
Full-year 2026 guidance reaffirmed: net sales down 4.5% to 2.5%, adjusted diluted EPS $2.40 to $2.65.
Second-quarter 2026 diluted EPS is expected at $0.20 to $0.25; CFO Eva Boratto steps down June 12 and Tom Javitch becomes interim CFO.
DICK'S reported first-quarter net sales of $5.16 billion, up 62.7% from a year earlier, with the Foot Locker acquisition included for the full quarter. GAAP diluted earnings per share rose to $3.54 from $3.24, but non-GAAP earnings per share fell to $2.90 from $3.37, and the company lowered its full-year GAAP earnings per share guidance while keeping its non-GAAP range unchanged.
First-quarter net sales $5.16 billion vs. $3.18 billion a year earlier; Foot Locker acquisition closed September 8, 2025
Diluted EPS $3.54 GAAP vs. $3.24 prior year; non-GAAP $2.90 vs. $3.37
Full-year 2026 GAAP diluted EPS guidance cut to $13.27 to $14.27 from $13.70 to $14.70; non-GAAP range of $13.50 to $14.50 unchanged
DICK'S Business comparable sales outlook low end raised to 2.5% from 2.0%; quarterly dividend of $1.25 per share payable June 26, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.